Lorvotuzumab

• Description :

  Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab) ) is a humanized monoclonal antibody that binds CD56 (NCAM1) . Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1].

• CAS Number :

  [339306-30-8]

• Product Name Alternative :

  Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)

• UNSPSC :

  12352203

• Target :

  ADC Antibody

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/lorvotuzumab.html

• Purity :

  99.77

• Solubility :

  10 mM in DMSO

• Smiles :

  [Lorvotuzumab]

• Molecular Weight :

  (146.44 kDa)

• References & Citations :

  [1]James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126 (24) :5303-5310.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2